[Anti-atherosclerotic effect].
作者信息
Takai Shinji, Miyazaki Mizuo
机构信息
Department of Pharmacology, Osaka Medical College.
出版信息
Nihon Rinsho. 2006 Jul;64 Suppl 5:518-23.
PMID:16895221
Abstract
摘要
相似文献
1
[Anti-atherosclerotic effect].
Nihon Rinsho. 2006 Jul;64 Suppl 5:518-23.
2
Cellular basis for therapeutic choices in heart failure.
Circulation. 2004 Oct 26;110(17):2559-61. doi: 10.1161/01.CIR.0000146803.14063.F7.
3
[New findings with RAS inhibitors in diabetic nephropathy].
Nihon Jinzo Gakkai Shi. 2007;49(5):485-90.
4
[The renin-angiotensin system].
Urologe A. 2009 Aug;48(8):925-33; quiz 934-5. doi: 10.1007/s00120-009-2091-4.
5
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Circulation. 2004 Nov 16;110(20):3281-8. doi: 10.1161/01.CIR.0000147274.83071.68.
6
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
J Hypertens. 2007 Jan;25(1):25-35. doi: 10.1097/HJH.0b013e3280113950.
7
Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Hypertens Res. 2008 Jan;31(1):59-67. doi: 10.1291/hypres.31.59.
8
9
[Effect of combination therapy with angiotensin II type I receptor and aldosterone receptor blockers in heart failure].
Nihon Rinsho. 2007 May 28;65 Suppl 5:145-9.
10
Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks.
J Hypertens. 2006 Nov;24(11):2157-9. doi: 10.1097/01.hjh.0000249690.88865.90.
Zotero 插件